Mitoxantrone Baxter

Mitoxantrone Baxter

mitoxantrone

Manufacturer:

Baxter Oncology

Distributor:

Transmedic
Concise Prescribing Info
Contents
Mitoxantrone HCl
Indications/Uses
Breast, ovarian & primary liver cell carcinoma, malignant lymphomas & acute leukaemias.
Dosage/Direction for Use
Slow IV Breast, ovarian & primary liver cell carcinoma, non-Hodgkin's lymphoma Monotherapy: 14 mg/m2 BSA initially for the 1st cycle. May be repeated after 21 days. Patient w/ diminished bone marrow reserves as a result of previous radiation &/or chemotherapy or those in a general poor state of health Initial dose should be reduced to 12 mg/m2 or corresponding to haematological parameters. (See lit.) Acute leukaemias Induction treatment in adults: 10-12 mg/m2 BSA daily for 5 consecutive days (total dose 50-60 mg/m2). Intrapleural instillation Single dose of 20-30 mg retained in the pleural cavity for 48 hr. The 1st treatment cycle is terminated if the vol of the drained exudate is <200 mL. If the vol is >200 mL, a further instillation of 30 mg is given. Max dose for 1 treatment cycle: 60 mg.
Special Precautions
Pancytopenia or severe infections at the florid stage, severe hepatic &/or renal insufficiency, patients previously treated w/ anthracyclines &/or irradiated on their mediastinum. History of severe heart disease. Combination w/ cardiotoxic cytostatic agent or other cardiotoxic medicament. Adequate contraception in patient of reproductive age during & for 3 mth after treatment. Monitor haematological parameters before each dose & at least once during each treatment cycle. After a total cumulative dose of >160 mg/m2 BSA, (in risk patients: 140 mg/m2), regular control of heart function by suitable methods should be carried out. Monitor liver function before & during treatment.
Adverse Reactions
Bone marrow depression, nausea, vomiting, alopecia, transient ECG alterations, acute arrhythmia, reduced left-ventricular ejection fraction, cardiac insufficiency, stomatitis, mucositis, hypersensitivity reactions, loss of appetite, GI disturbances & bleeding, fatigue, amenorrhoea, fever, dyspnoea, hepatic impairment. Transient changes in liver enzyme, serum creatinine & blood urea values. Blue-green urine discolouration.
Drug Interactions
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01DB07 - mitoxantrone ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.
Presentation/Packing
Form
Mitoxantrone Baxter inj 20 mg/10 mL
Packing/Price
(vial) 10 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in